Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Soliqua
| Field | Information |
|---|---|
| Medication Name | Soliqua |
| Generic Name | Insulin glargine/lixisenatide |
| Boxed/Label Warning | Risk of thyroid C-cell tumors with lixisenatide component. |
| Purpose | To improve blood sugar control in adults with type 2 diabetes mellitus. |
| Mechanism of Action | Combines a long-acting insulin analog (insulin glargine) and a GLP-1 receptor agonist (lixisenatide). Insulin glargine provides basal insulin, while lixisenatide enhances glucose-dependent insulin secretion, slows gastric emptying, and decreases postprandial glucagon secretion. |
| Dosage Forms | Injectable solution in a pre-filled pen. |
| Available Strengths | 100 units/mL insulin glargine and 33 mcg/mL lixisenatide |
| Dosage Frequency | Once daily, injected subcutaneously within the hour prior to the first meal of the day. |
| Common Side Effects | Hypoglycemia, nausea, nasopharyngitis, diarrhea, upper respiratory tract infection. |
| Serious Side Effects | Severe hypoglycemia, pancreatitis, allergic reactions, kidney problems, gallbladder problems. |
| Drug Interactions | Other antidiabetic agents (e.g., sulfonylureas, GLP-1 receptor agonists), beta-blockers, ACE inhibitors, ARBs, salicylates, alcohol. |
| Important Notes | Monitor blood glucose regularly. Educate patients about the signs and symptoms of hypoglycemia and how to treat it. Use caution in patients with a history of pancreatitis. |
| Storage | Store unopened pens in the refrigerator. Do not freeze. Once opened, store at room temperature for up to 28 days. |
| Missed Dose | If a dose is missed, take it as soon as you remember, unless it is close to the time of your next dose. Do not take a double dose to make up for a missed one. |
| Alternatives | Trulicity (dulaglutide), Ozempic (semaglutide), Lantus (insulin glargine), Victoza (liraglutide). |
Soliqua Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Trulicity (dulaglutide) | GLP-1 receptor agonist | Injectable medication; enhances insulin secretion and slows gastric emptying. |
| Ozempic (semaglutide) | GLP-1 receptor agonist | Injectable medication; promotes insulin release and reduces glucagon secretion. |
| Lantus (insulin glargine) | Long-acting insulin analog | Provides basal insulin; helps control blood sugar levels throughout the day. |
| Victoza (liraglutide) | GLP-1 receptor agonist | Injectable medication; improves blood sugar control and may promote weight loss. |
Soliqua Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Hypoglycemia | Severe hypoglycemia |
| Nausea | Pancreatitis |
| Diarrhea | Allergic reactions (rash, itching, swelling, difficulty breathing) |
| Nasopharyngitis | Kidney problems |
| Upper respiratory tract infection | Gallbladder problems |
Soliqua Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Type 2 Diabetes | 15 units (15 units of insulin glargine and 5 mcg of lixisenatide) | Individualized based on glycemic response, up to a maximum of 60 units (60 units of insulin glargine and 20 mcg of lixisenatide) | Inject subcutaneously once daily within the hour prior to the first meal of the day. Adjust dose according to blood glucose monitoring. |
Soliqua Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $35 |
| Without Insurance (U.S.) | $875 |
| From CPS | $313 |
